Get started
Work

1702P Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)

Year: 2024
Type: article
DOI: 10.1016/j.annonc.2024.08.1795
Authors: B.A. McGregor, M. Paul, W. Xie, W. Xu, M.A. Bilen, D.A. Braun, S. Berg, T. Zhang, R.R. McKay, D.F. McDermott, H. Hammers, T.K. Choueiri
Institutions: Dana-Farber Cancer Institute, Winship Cancer Institute, Yale Cancer Center, Yale University, The University of Texas Southwestern Medical Center, University of California San Diego, Beth Israel Deaconess Medical Center
Language: English
Field: Medicine
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, American Society of Clinical Oncology, Cleveland Clinic, Dana-Farber Cancer Institute, Exelixis, Society for Immunotherapy of Cancer, Incyte, Calithera Biosciences, NGM Biopharmaceuticals, Seagen, Invitae, Myrovlytis Trust, Eisai, Astellas Pharma, European Society for Medical Oncology, Institut Gustave-Roussy, Ipsen, Aptitude Health, Genentech, EMD Serono, Pharmacyclics, National Cancer Institute
OpenAlex ID: W4402704858
FWCI: 0.581
Cites:
Cited by: 2
Related to: 10